| Description | French coverage |
---|---|---|
Base case analysis | Vaccination coverage of MMR dose 1 and 2 | Dose 1: 90%; Dose 2: 80% |
Time for replacement (MMR by MMRV) | 3 years | |
Catch-up program | No catch-up | |
Exogenous/endogenous boosting | Included and relative weighting depends on scenario | |
Contact matrix | Empirical | |
Vaccine protection | Post-dose 1: 17 years; Post-dose 2: lifelong protection | |
Sensitivity analysis | Waning natural immunity (average duration 10 years – base case) changed to 2 and 20 years | bc: δ = 0.1 Low: δ = 0.05 High: δ = 0.5 |
Reactivation rate of infectious zoster, by age group for δ = 0.1 | ||
 0–4 years | 0.028 | |
 5–9 years | 0.009 | |
 10–14 years | 0.0068 | |
 15–24 years | 0.0035 | |
 25–44 years | 0.0033 | |
 45–64 years | 0.008 | |
 ≥65+ years | 0.016 | |
Reactivation rate of infectious zoster, by age group for δ = 0.5 | ||
 0–4 years | 0.00769 | |
 5–9 years | 0.00339 | |
 10–14 years | 0.00326 | |
 15–24 years | 0.00227 | |
 25–44 years | 0.00256 | |
 45–64 years | 0.00646 | |
 ≥65+ years | 0.01387 | |
Reactivation rate of infectious zoster, by age group for δ = 0.05 | ||
 0–4 years | 0.05478 | |
 5–9 years | 0.01666 | |
 10–14 years | 0.01183 | |
 15–24 years | 0.00548 | |
 25–44 years | 0.00453 | |
 45–64 years | 0.01035 | |
 ≥65+ years | 0.01991 |